Recent Diabetes Articles

Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension

Top

Tikkanen I, Narko K, Zeller C, et al; for the EMPA-REG BP Investigators. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2014;Epub ahead of print. DOI: 10.2337/dc14-1096.

Weight-loss therapy in type 2 diabetes effects of phentermine and topiramate extended-release

Top

Exclusive! Expert diabetes blog post from Silvio Inzucchi, MD. Garvey WT, Ryan DH, Bohannan NJV, et al. Weight loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37(12):3309-3316.

Effect of hypoglycemia on brain structure in people with type 2 diabetes: epidemiological analysis of the ACCORD-MIND MRI trial

Top

Zhang Z, Lovato J, Battapady H, et al. Effect of hypoglycemia on brain structure in people with type 2 diabetes:  epidemiological analysis of the ACCORD MIND MRI trial. Diabetes Care. 2014;37(12):3279-3285.

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study

Top

Henry RR, Rosenstock, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2014; Epub ahead of print. DOI: 10.2337/dc13-2955.

A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position

Top

Giorda CB, Nada E, Tartaglino B, Marafetti L, Gnavi R. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes Obes Metab. 2014;16:1041-1047.

Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012

Top

Geiss LS, Wang J, Cheng YJ, et al. Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA. 2014;312(12):1218-1226.

Incidence of remission in adults with type 2 diabetes: The Diabetes and Aging Study

Top

Karter AJ, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: The Diabetes and Aging Study. Diabetes Care. 2014; [ePub ahead of print]. doi: 10.2337/dc14-0874.

Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Espeland MA, Glick HA, Bertoni A, et al; for the Look AHEAD Research Group. Impact of an intensive lifestyle intervention on use and cost of medical services among overweight and obese adults with type 2 diabetes: The Action for Health in Diabetes. Diabetes Care. 2014;37:2548-2566.

Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study

Top

Exclusive! Expert diabetes blog post from Silvio E. Inzucchi, MD. Bedenis R, Price AH, Robertson CM, et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2014. [ePub ahead of print] doi: 10.2337/dc14-0908.

ADVANCE-ON: Follow-up of blood-pressure lowering and glucose control in type 2 diabetes

Top

Zoungas S, Chalmers J, Neal B, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;[epub ahead of print]. doi: 10.1056/NEJMoa1407963.

Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study

Top

Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol. 2014. [ePub ahead of print] doi: 10.1016/S2213-8587(14)70173-1.

Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study

Top

Cheng S, Claggett B, Correia AW, et al. Temporal trends in the population attributable risk for cardiovascular disease: The Atherosclerosis Risk in Communities Study. Circulation. 2014;130:820-828.

Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial

Top

Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care. 2014;37(9):2522-2532.

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases

Top

Dormuth CR, Filion KB, Paterson JM, et al; for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348:g3244.

Statins and the risk of diabetes: evidence from a large population-based cohort study

Top

Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37(8):2225-2232.

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the DPP-4 inhibitor saxagliptin

Top

Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl-peptidase-4 (DPP-4) inhibitor saxagliptin. Diabetes Care. 2014. DOI:10.2337/dc13-2546.

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications

Top

Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-2304.

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease

Top

Yarchoan M, Arnold SE. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Diabetes. 2014. DOI:10.2337/db14-0287.

Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease

Top

De Felice FG, Ferreira ST. Inflammation, defective insulin signaling, and mitochondrial dysfunction as common molecular denominators connecting type 2 diabetes to Alzheimer disease. Diabetes. 2014. DOI:10.2337/db13-1954.

Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI?

Top

Biessels GJ, Reijmer YD. Brain changes underlying cognitive dysfunction in diabetes: what can we learn from MRI? Diabetes. 2014. DOI:10.2337/db14-0384.

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin + MDI insulin

Top

Rosenstock J, Jelaska A, Frappin G, et al; on behalf of the EMPA-REG MDI Trial Investigators. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014. DOI:10.2337/dc13-3055.

Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial

Top

Jenkins DJA, Kendall CWC, Vuksan V, et al. Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial. Diabetes Care. 2014. DOI:10.2337/dc13-2990.

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

Top

Faillie J-L, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study. BMJ. 2014;348:g2780. doi 10.1136/bmj.g2780.


Last Modified: 08/14/2014